Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS) and Opko Health (OPK).
Emergent Biosolutions (EBS)
In a report released today, Keay Nakae from Chardan Capital downgraded Emergent Biosolutions to Hold, with a price target of $112.00. The company’s shares closed last Thursday at $117.06.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 35.2% and a 57.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and NeuBase Therapeutics.
Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $111.33.
See today’s analyst top recommended stocks >>
Opko Health (OPK)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health, with a price target of $8.00. The company’s shares closed last Thursday at $5.36.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 14.0% and a 56.8% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Anika Therapeutics, and Lemaitre Vascular.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opko Health with a $8.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
